Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína2. fázis

Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Tianjin (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
160 fő, tervezett
Kezdés
2026. jan. 28.
Várható befejezés
2028. nov.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Daratumumab(Anti-CD38 Monoclonal Antibody)
  • Rituximab
A regiszteradat frissítve
2026. február 11.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary immune thrombocytopenia (ITP, a low platelet count caused by the immune system) whose steroid treatment did not work or stopped working. It compares rituximab plus daratumumab with rituximab alone.

Életkor
18 years or older
Nem
Male or female
A betegség stádiuma
Primary ITP diagnosed at least three months before joining. ECOG performance status of 2 or less (able to care for yourself). Heart function NYHA class 2 or less.
Korábbi kezelés
Glucocorticoid (steroid) treatment must have failed, stopped working, or the disease came back. Emergency ITP treatment must have ended at least 2 weeks before the first dose. Azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus and similar drugs must be stopped at least 4 weeks before. Rituximab or other CD20 antibodies must have been stopped for more than 6 months. Spleen removal must be more than 6 months ago. Steady glucocorticoids (≤0.5 mg/kg prednisone or equivalent) or TPO receptor agonists are allowed if stable for at least 4 weeks.
Biomarker vagy leletérték
Platelet count below 30×10^9/L within 48 hours before the first dose, and in at least two tests at least 1 week apart during screening. Liver and kidney tests below 1.5 times the upper limit of normal.

A részvétel fő kizáró okai

  • HIV positive, or uncontrolled active infection such as hepatitis B, hepatitis C, cytomegalovirus, EB virus or syphilis
  • Severe bleeding, such as bleeding in the brain or gut, or coughing up blood
  • Blood clot diseases, uncontrolled heart disease, or serious organ disease such as cancer or organ failure
  • Past allogeneic stem cell transplant or organ transplant
  • Pregnant or breastfeeding, or taking antiplatelet drugs

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years, male or female
  • Before enrollment, the subjects have been clinically diagnosed with primary immune thrombocytopenia for no less than three months according to the American Society of Hematology guidelines 2011 Evidence-Based Practice Guideline (Neunert et al. 2011) or the International Consensus Report for the Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as applicable locally
  • Subjects with a platelet count of <30×10\^9/L within the 48 hours prior to the first dose of the study drug;The platelet count of at least two separate assessments (at least 1 week apart) <30×10\^9/L during the screening visit
  • Patients have failed glucocorticoid therapy (either due to inefficacy, efficacy could not be maintained, or relapse)
  • Previous emergency treatment for ITP (e.g., methylprednisolone, platelet, gamma globulin infusion) must have been completed at least 2 weeks before the first dose
  • Hepatic and renal function (e.g., alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine) <1.5 times the upper limit of normal (ULN)
  • ECOG performance status score of ≤2
  • Cardiac function: New York Heart Association (NYHA) class ≤2
  • Enrollment of subjects receiving maintenance therapy is permitted, including glucocorticoids (≤0.5 mg/kg of prednisone or equivalent) or TPO receptor agonists, but the concomitant medication must have been stable for a minimum of 4 weeks prior to the initial infusion of the study drug; Azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first dose; CD20 monoclonal antibody such as rituximab must have been stopped for more than 6 months; the interval between splenectomy and first administration need to be more than 6 months
  • For fertile female patients, a negative pregnancy test result is required. Fertile female and male patients must use effective contraception separately during the study and for 90 days after the cessation of study drug treatment
  • Subjects comprehensively understand and can adhere to the study protocol requirements and willingly signed the informed consent form

Ki nem vehet részt

  • Those who have received allogeneic stem cell transplantation or organ transplantation in the past
  • Patients taking antiplatelet drugs at the same time
  • Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases
  • HIV positive
  • Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive
  • Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc
  • At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled
  • Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis
  • atients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up
  • Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.)
  • Patients with septicemia or other irregular severe bleeding
  • Subjects with a known allergy to medications were used in the trial or excipients
  • Any other conditions unsuitable for participation in this study, as assessed by the investigator
  • Patients whose toxic symptoms caused by pre-trial treatment have not disappeared
  • Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients

Helyszínek itt: Kína

  • Chinese Academy of Medical Science and Blood Disease HospitalTianjin, KínaContact: Lei Zhang, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This randomized, open-label study aim to compare the efficacy and safety of rituximab combining anti-CD38 monoclonal antibody with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.

A vizsgálat 2 csoportja

  • rituximab combined with Daratumumab(anti-CD38 monoclonal antibody)A vizsgált kezelés

    Rituximab (375mg/m2) was given once (day1) and a Daratumumab (16mg/kg) was given four times (day8,15,22,29).

    Kezelés: Daratumumab(Anti-CD38 Monoclonal Antibody) és Rituximab

  • rituximabMár használt kezelés, összehasonlításként

    Rituximab (375mg/m2) was given once.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Open-label Study To Compare The Efficacy And Safety Of Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in ITP Patients Who Failed or Relapsed After Glucocorticoid Therapy
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. február 11.